Gregory Renza
Stock Analyst at Truist Securities
(3.39)
# 959
Out of 5,124 analysts
257
Total ratings
41.71%
Success rate
5.76%
Average return
Main Sectors:
Stocks Rated by Gregory Renza
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $820 → $818 | $785.51 | +4.14% | 3 | Feb 2, 2026 | |
| GILD Gilead Sciences | Maintains: Buy | $140 → $145 | $152.50 | -4.92% | 2 | Jan 27, 2026 | |
| CGON CG Oncology | Maintains: Buy | $62 → $66 | $50.36 | +31.06% | 5 | Jan 12, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $41 → $40 | $29.25 | +36.75% | 13 | Jan 8, 2026 | |
| AMGN Amgen | Maintains: Hold | $318 → $319 | $384.32 | -17.00% | 19 | Jan 8, 2026 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $59 → $60 | $32.17 | +86.51% | 14 | Jan 6, 2026 | |
| AGIO Agios Pharmaceuticals | Maintains: Buy | $32 → $38 | $26.53 | +43.23% | 8 | Dec 24, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Buy | $14 → $18 | $9.74 | +84.80% | 5 | Dec 11, 2025 | |
| CATX Perspective Therapeutics | Assumes: Buy | $8 → $12 | $4.71 | +154.78% | 7 | Nov 24, 2025 | |
| NRIX Nurix Therapeutics | Assumes: Buy | $23 → $30 | $16.85 | +78.04% | 12 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $11.61 | +149.78% | 10 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $5.70 | +92.98% | 7 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $103.59 | +35.15% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.78 | +55.71% | 2 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $10 | $5.66 | +76.68% | 4 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $353.92 | +13.02% | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $24.52 | +107.99% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $140 | $117.67 | +18.98% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $45 → $50 | $43.90 | +13.90% | 11 | Jul 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $26 | $23.56 | +10.36% | 16 | May 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $8 | $4.01 | +99.50% | 12 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $5 | $1.66 | +201.20% | 11 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $182 → $172 | $165.50 | +3.93% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $113 → $38 | $72.40 | -48.20% | 14 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $7.69 | +56.05% | 6 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $6.67 | +109.90% | 10 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Sector Perform | $18 | $21.00 | -14.29% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $48 | $1.35 | +3,455.56% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $110 → $20 | $6.91 | +189.44% | 7 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $16 | $0.90 | +1,679.76% | 7 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $16 | $12.79 | +25.10% | 5 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $2,160 → $180 | $14.19 | +1,168.50% | 4 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $100 → $80 | $0.69 | +11,494.20% | 5 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $105 → $30 | $0.30 | +9,833.77% | 3 | Jun 2, 2020 |
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Buy
Price Target: $820 → $818
Current: $785.51
Upside: +4.14%
Gilead Sciences
Jan 27, 2026
Maintains: Buy
Price Target: $140 → $145
Current: $152.50
Upside: -4.92%
CG Oncology
Jan 12, 2026
Maintains: Buy
Price Target: $62 → $66
Current: $50.36
Upside: +31.06%
Viridian Therapeutics
Jan 8, 2026
Maintains: Buy
Price Target: $41 → $40
Current: $29.25
Upside: +36.75%
Amgen
Jan 8, 2026
Maintains: Hold
Price Target: $318 → $319
Current: $384.32
Upside: -17.00%
IDEAYA Biosciences
Jan 6, 2026
Maintains: Buy
Price Target: $59 → $60
Current: $32.17
Upside: +86.51%
Agios Pharmaceuticals
Dec 24, 2025
Maintains: Buy
Price Target: $32 → $38
Current: $26.53
Upside: +43.23%
Fulcrum Therapeutics
Dec 11, 2025
Maintains: Buy
Price Target: $14 → $18
Current: $9.74
Upside: +84.80%
Perspective Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $8 → $12
Current: $4.71
Upside: +154.78%
Nurix Therapeutics
Nov 24, 2025
Assumes: Buy
Price Target: $23 → $30
Current: $16.85
Upside: +78.04%
Nov 24, 2025
Initiates: Buy
Price Target: $29
Current: $11.61
Upside: +149.78%
Nov 24, 2025
Initiates: Buy
Price Target: $11
Current: $5.70
Upside: +92.98%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $103.59
Upside: +35.15%
Nov 24, 2025
Initiates: Buy
Price Target: $9
Current: $5.78
Upside: +55.71%
Nov 24, 2025
Initiates: Hold
Price Target: $10
Current: $5.66
Upside: +76.68%
Nov 24, 2025
Initiates: Buy
Price Target: $400
Current: $353.92
Upside: +13.02%
Nov 24, 2025
Initiates: Buy
Price Target: $51
Current: $24.52
Upside: +107.99%
Nov 24, 2025
Initiates: Buy
Price Target: $140
Current: $117.67
Upside: +18.98%
Jul 8, 2025
Downgrades: Sector Perform
Price Target: $45 → $50
Current: $43.90
Upside: +13.90%
May 19, 2025
Reiterates: Outperform
Price Target: $26
Current: $23.56
Upside: +10.36%
May 15, 2025
Reiterates: Outperform
Price Target: $8
Current: $4.01
Upside: +99.50%
May 14, 2025
Reiterates: Sector Perform
Price Target: $5
Current: $1.66
Upside: +201.20%
May 7, 2025
Maintains: Outperform
Price Target: $182 → $172
Current: $165.50
Upside: +3.93%
Apr 16, 2025
Maintains: Sector Perform
Price Target: $113 → $38
Current: $72.40
Upside: -48.20%
Mar 26, 2025
Reiterates: Outperform
Price Target: $12
Current: $7.69
Upside: +56.05%
Mar 21, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $6.67
Upside: +109.90%
Jan 14, 2025
Reiterates: Sector Perform
Price Target: $18
Current: $21.00
Upside: -14.29%
Jan 9, 2025
Maintains: Outperform
Price Target: $68 → $48
Current: $1.35
Upside: +3,455.56%
Nov 5, 2024
Downgrades: Sector Perform
Price Target: $110 → $20
Current: $6.91
Upside: +189.44%
Aug 14, 2024
Reiterates: Outperform
Price Target: $16
Current: $0.90
Upside: +1,679.76%
Mar 15, 2024
Maintains: Outperform
Price Target: $19 → $16
Current: $12.79
Upside: +25.10%
Jun 27, 2023
Downgrades: Sector Perform
Price Target: $2,160 → $180
Current: $14.19
Upside: +1,168.50%
Mar 16, 2022
Maintains: Sector Perform
Price Target: $100 → $80
Current: $0.69
Upside: +11,494.20%
Jun 2, 2020
Downgrades: Sector Perform
Price Target: $105 → $30
Current: $0.30
Upside: +9,833.77%